Heron Therapeutics, Inc. (HRTX) Stock Grade

About Heron Therapeutics, Inc.'s fundamentals

Heron Therapeutics is a biotechnology company with a market capitalization of $216.7 million that generated 7.4% year-over-year revenue growth in its latest period. However, the company operates at a net loss, with a negative net margin of -13.0%, indicating that expenses exceed revenues. The company does not pay a dividend, and standard profitability metrics like P/E ratio and return on equity are not applicable due to the net loss position. This financial profile is typical for development-stage biotech firms that prioritize research and product development over near-term profitability.